

(10) International Publication Number
WO 2017/007943 A1(43) International Publication Date
12 January 2017 (12.01.2017)

(51) International Patent Classification:

C07D 498/04 (2006.01) A61P 19/00 (2006.01)
A61K 31/4353 (2006.01)

(21) International Application Number:

PCT/US2016/041345

(22) International Filing Date:

7 July 2016 (07.07.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/190,145 8 July 2015 (08.07.2015) US

(71) Applicants: **DAIICHI SANKYO COMPANY, LIMITED** [JP/JP]; 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP). **SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE** [US/US]; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US).(72) Inventors: **MIYAZAKI, Shojiro**; c/o Daiichi Sankyo Company, Limited, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710 (JP). **YAMAMOTO, Yuko**; c/o Daiichi Sankyo Company, Limited, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710 (JP). **SUZUKI, Keisuke**; c/o Daiichi Sankyo Company, Limited, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710 (JP). **INUI, Masaharu**; c/o Daiichi Sankyo Company, Limited, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710 (JP). **IZUMI, Masanori**; c/o Daiichi Sankyo Company, Limited, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710 (JP). **SOMA, Kaori**; c/o Daiichi Sankyo Company, Limited, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710 (JP). **PINKERTON, Anthony**; c/o Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037 (US). **SHINOZAKI, Taeko**; c/o Daiichi Sankyo

Company, Limited, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710 (JP).

(74) Agent: **RENZONI, George, E.**; Christensen O'Connor Johnson Kindness PLLC, 1201 Third Avenue, Suite 3600, Seattle, WA 98101 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

[Continued on next page]

(54) Title: PYRIDO-OXAZINONE DERIVATIVES AS TNAP INHIBITORS



(57) Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R¹ represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R² and R³ are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R⁴ and R⁵ are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R⁶ represents a hydrogen atom or the like, each R⁷ may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents -CH=, -C(-R⁷)=, or -N=, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.

- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*